This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
public health | 308 |
respiratory syndrome | 301 |
acute respiratory | 289 |
severe acute | 246 |
global health | 194 |
hong kong | 148 |
infl uenza | 145 |
doc id | 140 |
lancet doi | 140 |
cord uid | 140 |
syndrome coronavirus | 122 |
novel coronavirus | 118 |
health care | 104 |
risk factors | 102 |
world health | 98 |
international health | 87 |
health systems | 83 |
disease control | 80 |
middle east | 79 |
coronavirus disease | 76 |
pregnant women | 75 |
systematic review | 75 |
infectious diseases | 71 |
competing interests | 70 |
health organization | 66 |
east respiratory | 64 |
health workers | 64 |
intensive care | 60 |
care workers | 60 |
southeast asia | 60 |
fi rst | 59 |
chandipura virus | 59 |
eff orts | 58 |
health regulations | 58 |
cognitive impairment | 57 |
controlled trial | 55 |
electron microscopy | 53 |
national health | 53 |
ebola virus | 52 |
saudi arabia | 52 |
cohort study | 51 |
blood pressure | 50 |
health emergency | 49 |
cov infection | 49 |
international concern | 48 |
health services | 48 |
emergency room | 47 |
fi gure | 47 |
respiratory tract | 46 |
health security | 46 |
randomised controlled | 45 |
infectious disease | 45 |
avian infl | 45 |
nucleocapsid protein | 43 |
clinical trials | 42 |
fi nancing | 42 |
severe covid | 41 |
human rights | 41 |
epithelial cells | 41 |
communicable diseases | 41 |
viral rna | 41 |
immune response | 41 |
data collection | 41 |
increased risk | 40 |
ebola outbreak | 40 |
human beings | 40 |
symptom onset | 40 |
dementia risk | 40 |
income countries | 39 |
emergency committee | 39 |
cognitive decline | 38 |
child health | 38 |
virus disease | 38 |
hiv aids | 36 |
aff ected | 36 |
influenza viruses | 35 |
social distancing | 35 |
health system | 35 |
virus infection | 35 |
adverse events | 35 |
uenza virus | 35 |
aged years | 34 |
data analysis | 34 |
eff ective | 34 |
ng ml | 34 |
diffuse alveolar | 34 |
west africa | 33 |
member states | 33 |
alveolar damage | 33 |
eff ect | 32 |
diff erent | 32 |
maternal mortality | 32 |
mild cognitive | 32 |
air pollution | 32 |
respiratory distress | 32 |
physical distancing | 32 |
poliomyelitis eradication | 31 |
climate change | 31 |
influenza virus | 31 |
clinical features | 31 |
mental health | 31 |
consequential medical | 31 |
medical event | 30 |
case fatality | 30 |
patients infected | 30 |
older people | 30 |
respiratory infections | 30 |
avian influenza | 30 |
community health | 30 |
ncov infection | 30 |
influenza vaccine | 29 |
south korea | 29 |
identifi ed | 29 |
serum samples | 29 |
disease outbreaks | 29 |
sex workers | 28 |
million people | 28 |
patients receiving | 28 |
developing countries | 28 |
physical activity | 27 |
contact tracing | 27 |
one patient | 27 |
sars patients | 27 |
human security | 27 |
people living | 27 |
fatality rate | 27 |
situ hybridisation | 27 |
controlled trials | 27 |
within days | 26 |
incubation period | 26 |
clinical characteristics | 26 |
health assembly | 26 |
risk factor | 26 |
age years | 26 |
eff ects | 26 |
decision making | 26 |
confi rmed | 26 |
world bank | 26 |
nursing homes | 26 |
distress syndrome | 26 |
zika virus | 25 |
risk assessment | 25 |
core capacities | 25 |
neutralising antibodies | 25 |
spike protein | 25 |
influenza vaccination | 25 |
fi nancial | 25 |
older adults | 25 |
child mortality | 25 |
vertical transmission | 25 |
mg kg | 25 |
respiratory syncytial | 25 |
mild ari | 24 |
health authorities | 24 |
immune responses | 24 |
south africa | 24 |
new york | 24 |
clinical trial | 24 |
clinical improvement | 24 |
policy makers | 24 |
offi ce | 24 |
human metapneumovirus | 23 |
supportive care | 23 |
infection control | 23 |
many countries | 23 |
among patients | 23 |
care systems | 23 |
mechanical ventilation | 22 |
general population | 22 |
emerging infectious | 22 |
influenza vaccines | 22 |
health equity | 22 |
virus infections | 22 |
study design | 22 |
care unit | 22 |
health aid | 22 |
united states | 22 |
primary care | 22 |
cardiovascular disease | 21 |
viral particles | 21 |
health outcomes | 21 |
six patients | 21 |
new coronavirus | 21 |
infected patients | 21 |
control measures | 21 |
health emergencies | 21 |
mortality rates | 21 |
polio eradication | 21 |
spike polypeptide | 21 |
hospital admissions | 21 |
confirmed cases | 21 |
medical teams | 21 |
healthy adults | 21 |
eradication initiative | 20 |
three patients | 20 |
sars coronavirus | 20 |
african countries | 20 |
covid infection | 20 |
nine patients | 20 |
chest ct | 20 |
sars outbreak | 20 |
anticancer treatments | 20 |
recombinant nucleocapsid | 20 |
confirmed covid | 19 |
care facilities | 19 |
vero cells | 19 |
mean age | 19 |
people aged | 19 |
family members | 19 |
critically ill | 19 |
ill patients | 19 |
immunofluorescence assay | 19 |
syncytial virus | 19 |
brain injury | 19 |
arab world | 19 |
neutralising antibody | 19 |
adult population | 18 |
clinical course | 18 |
clinical data | 18 |
care units | 18 |
lymph nodes | 18 |
lower respiratory | 18 |
cohort studies | 18 |
might also | 18 |
time rt | 18 |
human infection | 18 |
democratic republic | 18 |
highly pathogenic | 18 |
health service | 18 |
will require | 18 |
randomized controlled | 18 |
care system | 18 |
respiratory infection | 18 |
throat swab | 18 |
viral replication | 18 |
antiretroviral therapy | 18 |
cognitive function | 18 |
sierra leone | 18 |
remdesivir group | 18 |
care homes | 18 |
health interventions | 18 |
civil society | 18 |
maternal deaths | 17 |
primary health | 17 |
progress towards | 17 |
mr assange | 17 |
hearing loss | 17 |
incident dementia | 17 |
us centers | 17 |
critical interventions | 17 |
mass gatherings | 17 |
human transmission | 17 |
hospital admission | 17 |
myocardial infarction | 17 |
human resources | 17 |
like particles | 17 |
medical care | 17 |
like illness | 17 |
high risk | 17 |
social care | 17 |
one study | 17 |
receiving dialysis | 17 |
global public | 17 |
outbreak response | 17 |
social contact | 17 |
neuropsychiatric symptoms | 17 |
natural history | 17 |
viral load | 17 |
clinical symptoms | 17 |
health professionals | 17 |
benefi ts | 17 |
health goals | 16 |
private sector | 16 |
took part | 16 |
index case | 16 |
saharan africa | 16 |
upper respiratory | 16 |
icu patients | 16 |
cov pneumonia | 16 |
blood donors | 16 |
health commission | 16 |
data interpretation | 16 |
traumatic brain | 16 |
viral infection | 16 |
alcohol consumption | 16 |
weight loss | 16 |
previous studies | 16 |
coronavirus infection | 16 |
ethnic racial | 16 |
clinical samples | 16 |
two patients | 16 |
per ml | 16 |
drug administration | 16 |
fi ndings | 16 |
early stages | 16 |
malaria control | 16 |
mortality rate | 16 |
reverse genetics | 16 |
viral sequences | 16 |
universal health | 15 |
mononuclear cells | 15 |
young children | 15 |
pandemic response | 15 |
heart disease | 15 |
governmental organisations | 15 |
health measures | 15 |
past years | 15 |
respiratory illness | 15 |
economic growth | 15 |
see online | 15 |
health community | 15 |
tissue samples | 15 |
political leadership | 15 |
elderly people | 15 |
gender equality | 15 |
lung tissue | 15 |
health initiatives | 15 |
healthy blood | 15 |
diff erences | 15 |
modifiable risk | 15 |
normal range | 15 |
th century | 15 |
balkan nephropathy | 15 |
millennium development | 15 |
affected countries | 15 |
disease outbreak | 15 |
case definition | 15 |
cov infections | 14 |
later life | 14 |
virus isolation | 14 |
respiratory failure | 14 |
accountability commission | 14 |
population density | 14 |
rabies vaccine | 14 |
classifi cation | 14 |
global response | 14 |
severe pneumonia | 14 |
control group | 14 |
year follow | 14 |
clinical practice | 14 |
infected cells | 14 |
surge capacity | 14 |
executive board | 14 |
coronavirus pneumonia | 14 |
blot assays | 14 |
global community | 14 |
states parties | 14 |
human diploid | 14 |
cognitive training | 14 |
east asia | 14 |
health problems | 14 |
will take | 14 |
clinical management | 14 |
adverse effects | 14 |
poliovirus vaccine | 14 |
sars virus | 14 |
health promotion | 14 |
vaccine candidates | 14 |
four patients | 14 |
neuraminidase inhibitors | 14 |
cancer patients | 14 |
pandemic influenza | 14 |
transmission potential | 13 |
pulmonary disease | 13 |
interferon beta | 13 |
respiratory pathogens | 13 |
national governments | 13 |
cell lines | 13 |
child deaths | 13 |
diffi cult | 13 |
endothelial cells | 13 |
treatment protocol | 13 |
will need | 13 |
united nations | 13 |
degradation products | 13 |
us adult | 13 |
herbal drugs | 13 |
reproduction number | 13 |
africa cdc | 13 |
nine pregnant | 13 |
influenza pandemic | 13 |
mm hg | 13 |
median age | 13 |
national institute | 13 |
vaccine development | 13 |
observational studies | 13 |
close contact | 13 |
action plan | 13 |
us dialysis | 13 |
protective equipment | 13 |
lung injury | 13 |
foreign aid | 13 |
two studies | 13 |
among people | 13 |
antibody responses | 13 |
risk tolerance | 13 |
per day | 13 |
person transmission | 13 |
disease surveillance | 13 |
vulnerable populations | 13 |
child survival | 13 |
cognitive reserve | 13 |
blood samples | 13 |
aff airs | 13 |
antibody titres | 13 |
igg antibodies | 13 |
emergency response | 13 |
tract infections | 13 |
dialysis population | 12 |
without dementia | 12 |
modelling study | 12 |
long term | 12 |
health workforce | 12 |
global fund | 12 |
critical intervention | 12 |
health coverage | 12 |
samples obtained | 12 |
hdcs vaccine | 12 |
signifi cantly | 12 |
indirect immunofluorescence | 12 |
effi cacy | 12 |
health threats | 12 |
prospective cohort | 12 |
monoclonal antibodies | 12 |
cord blood | 12 |
case series | 12 |
ebola response | 12 |
informed consent | 12 |
nucleic acid | 12 |
fi nal | 12 |
care providers | 12 |
mass gathering | 12 |
respiratory coronavirus | 12 |
development goals | 12 |
developed countries | 12 |
regional offi | 12 |
coronavirus infections | 12 |
severe illness | 12 |
prospective study | 12 |
human immunodeficiency | 12 |
west african | 12 |
respiratory viruses | 12 |
higher risk | 12 |
human disease | 12 |
immunodeficiency virus | 12 |
infection among | 12 |
health challenges | 12 |
pandemic infl | 12 |
early detection | 12 |
placebo group | 12 |
zone iv | 12 |
specific antibodies | 12 |
mg dl | 12 |
clinical outcomes | 12 |
recombinant adenovirus | 12 |
breast cancer | 12 |
medical research | 12 |
kg daily | 12 |
throat swabs | 12 |
antiviral drugs | 12 |
patients admitted | 12 |
wide range | 12 |
associated coronavirus | 11 |
technical assistance | 11 |
hiv infection | 11 |
personal protective | 11 |
latin america | 11 |
cytokine storm | 11 |
pulsed methylprednisolone | 11 |
evidence synthesis | 11 |
andhra pradesh | 11 |
adenovirus type | 11 |
disease severity | 11 |
candidate vaccines | 11 |
health governance | 11 |
health status | 11 |
old woman | 11 |
odds ratio | 11 |
health research | 11 |
moral values | 11 |
international spread | 11 |
health information | 11 |
stranded rna | 11 |
potentially modifiable | 11 |
animal models | 11 |
antibiotic treatment | 11 |
manuscript writing | 11 |
mortality reduction | 11 |
traditional chinese | 11 |
medical records | 11 |
herd immunity | 11 |
adult volunteers | 11 |
adult patients | 11 |
randomised trial | 11 |
global polio | 11 |
lung biopsy | 11 |
chest radiograph | 11 |
human infections | 11 |
remainder plasma | 11 |
well tolerated | 11 |
johns hopkins | 11 |
retrospective cohort | 11 |
multiple sclerosis | 11 |
high mortality | 11 |
health response | 11 |
defi ned | 11 |
chinese medicine | 11 |
evidence base | 11 |
local health | 11 |
social justice | 11 |
study group | 11 |
diagnostic tests | 11 |
septic shock | 11 |
cause dementia | 11 |
global system | 11 |
defi nition | 11 |
ace inhibitors | 11 |
antibiotic use | 11 |
standing emergency | 11 |
among children | 11 |
virus particles | 11 |
cell cultures | 11 |
wild poliovirus | 11 |
lamina propria | 11 |
healthcare workers | 11 |
renal failure | 11 |
procalcitonin concentrations | 11 |
i declare | 11 |
future studies | 10 |
transmission dynamics | 10 |
severe disease | 10 |
cumulative number | 10 |
health eff | 10 |
type pneumocytes | 10 |
kidney disease | 10 |
international community | 10 |
palliative chemotherapy | 10 |
structural racism | 10 |
peripheral blood | 10 |
multiple organ | 10 |
global eradication | 10 |
fi nance | 10 |
reference virus | 10 |
less likely | 10 |
review committee | 10 |
patients showed | 10 |
human health | 10 |
webfi gure | 10 |
traditional medicine | 10 |
social protection | 10 |
reported cases | 10 |
million children | 10 |
mitigation strategies | 10 |
longitudinal studies | 10 |
chinese government | 10 |
status epilepticus | 10 |
raas inhibitors | 10 |
lessons learned | 10 |
human infl | 10 |
disposition classifi | 10 |
oxygen therapy | 10 |
sample size | 10 |
risk groups | 10 |
cardiovascular diseases | 10 |
human coronavirus | 10 |
cation system | 10 |
attack rates | 10 |
information sharing | 10 |
among older | 10 |
per minute | 10 |
general public | 10 |
lancet commission | 10 |
per capita | 10 |
within weeks | 10 |
core functions | 10 |
cov outbreak | 10 |
asian nations | 10 |
dementia incidence | 10 |
universal coverage | 10 |
health institute | 10 |
medical center | 10 |
antimicrobial resistance | 10 |
five patients | 10 |
tagged recombinant | 10 |
data sources | 10 |
case studies | 10 |
mg daily | 10 |
hiv prevention | 10 |
health insurance | 10 |
full access | 10 |
respiratory symptoms | 10 |
ncov pneumonia | 10 |
serum concentrations | 10 |
tissue culture | 10 |
term care | 10 |
recent chemotherapy | 10 |
care settings | 10 |
chronic diseases | 10 |
receptor binding | 10 |
newborn babies | 10 |
oxygen saturation | 10 |
rna viruses | 10 |
interim guidance | 10 |
obstructive pulmonary | 10 |
confi dence | 10 |
probable sars | 10 |
healthy adult | 10 |
julian assange | 10 |
transmission electron | 10 |
two groups | 10 |
natural disasters | 10 |
tobacco control | 10 |
security council | 10 |
monoclonal antibody | 10 |
convalescent plasma | 10 |
cervical cancer | 10 |
neonatal mortality | 10 |
patients developed | 10 |
virus transmission | 9 |
deaths among | 9 |
community engagement | 9 |
cardiovascular risk | 9 |
sustainable development | 9 |
health metrics | 9 |
amniotic fluid | 9 |
chinese center | 9 |
one case | 9 |
phylogenetic analysis | 9 |
inactivated influenza | 9 |
upper limit | 9 |
planetary health | 9 |
children younger | 9 |
will help | 9 |
may also | 9 |
severe ari | 9 |
ihr emergency | 9 |
per population | 9 |
attack rate | 9 |
people per | 9 |
primer pair | 9 |
disease threats | 9 |
good health | 9 |
median time | 9 |
point scale | 9 |
major outbreak | 9 |
porcine respiratory | 9 |
viral sepsis | 9 |
apgar score | 9 |
preventive measures | 9 |
diploid cell | 9 |
lives saved | 9 |
antiviral treatment | 9 |
respiratory disease | 9 |
life course | 9 |
twice daily | 9 |
chronic obstructive | 9 |
south african | 9 |
per year | 9 |
foreign policy | 9 |
feminist economic | 9 |
capacity building | 9 |
alveolar macrophages | 9 |
cellular immune | 9 |
african union | 9 |
health action | 9 |
eff ort | 9 |
major disease | 9 |
body mass | 9 |
health facilities | 9 |
randomized clinical | 9 |
genome sequence | 9 |
high quality | 9 |
older children | 9 |
offi cial | 9 |
randomly assigned | 9 |
hazard ratio | 9 |
designated hospital | 9 |
jinyintan hospital | 9 |
inhaled zanamivir | 9 |
global spread | 9 |
times higher | 9 |
cause mortality | 9 |
caesarean section | 9 |
high concentrations | 9 |
distancing measures | 9 |
biomedical research | 9 |
viruses isolated | 9 |
concern declaration | 9 |
close contacts | 9 |
serious adverse | 9 |
ct findings | 9 |
european countries | 9 |
clinical specimens | 9 |
developed severe | 9 |
previous study | 9 |
economic development | 9 |
cleavage site | 9 |
health risks | 9 |
reduce transmission | 9 |
colleagues reported | 9 |
antibody test | 9 |
human cases | 9 |
cell culture | 9 |
webappendix pp | 9 |
positive results | 9 |
working group | 9 |
antisense probes | 9 |
us billion | 9 |
human influenza | 9 |
viral infections | 9 |
emergency department | 9 |
laboratory testing | 9 |
health policy | 9 |
health sector | 9 |
health surveillance | 9 |
small intestine | 9 |
emerging infections | 9 |
authors contributed | 9 |
developing dementia | 9 |
eff ectiveness | 9 |
obstetric care | 9 |
primary outcome | 9 |
drug use | 9 |
viral shedding | 9 |
virus vaccines | 9 |
large numbers | 9 |
general practice | 8 |
chicken eggs | 8 |
organ failure | 8 |
lung pathology | 8 |
international travel | 8 |
community transmission | 8 |
health programmes | 8 |
tested positive | 8 |
health conditions | 8 |
corresponding author | 8 |
severe respiratory | 8 |
will probably | 8 |
converting enzyme | 8 |
bronchitis virus | 8 |
us million | 8 |
huanan seafood | 8 |
hearing aids | 8 |
samsung medical | 8 |
acquired immunodeficiency | 8 |
mitigation measures | 8 |
suspected cases | 8 |
mask use | 8 |
two cases | 8 |
north america | 8 |
preliminary report | 8 |
asean countries | 8 |
southeast asian | 8 |
inactivated vaccines | 8 |
descriptive study | 8 |
igg antibody | 8 |
immunodeficiency syndrome | 8 |
among health | 8 |
adults aged | 8 |
communicable disease | 8 |
ebola epidemic | 8 |
risk individuals | 8 |
ascend clinical | 8 |
small number | 8 |
west nile | 8 |
york times | 8 |
rabies virus | 8 |
family planning | 8 |
systematic reviews | 8 |
situation report | 8 |
japanese encephalitis | 8 |
australia antigen | 8 |
third trimester | 8 |
many years | 8 |
sars epidemic | 8 |
severely ill | 8 |
invasive ventilation | 8 |
searched pubmed | 8 |
development goal | 8 |
signifi cant | 8 |
igm antibodies | 8 |
level data | 8 |
research centre | 8 |
confl icts | 8 |
pneumonia cases | 8 |
two formulations | 8 |
printed journal | 8 |
high levels | 8 |
sars cases | 8 |
urine samples | 8 |
national public | 8 |
lymph node | 8 |
years ago | 8 |
disease transmission | 8 |
face mask | 8 |
political leaders | 8 |
dementia prevention | 8 |
clinically diagnosed | 8 |
human coronaviruses | 8 |
study provides | 8 |
case study | 8 |
evidence suggests | 8 |
temporary recommendations | 8 |
animal health | 8 |
health laboratory | 8 |
development assistance | 8 |
based study | 8 |
social media | 8 |
evidence exists | 8 |
alcoholic steatohepatitis | 8 |
infection prevention | 8 |
cell lymphoma | 8 |
clinical presentations | 8 |
life expectancy | 8 |
national institutes | 8 |
seropositive individuals | 8 |
type diabetes | 8 |
coronavirus outbreak | 8 |
health inequities | 8 |
seroprevalence surveys | 8 |
unpaid care | 8 |
com vol | 8 |
antibody response | 8 |
past decade | 8 |
national income | 8 |
proinflammatory cytokines | 8 |
systematic analysis | 8 |
cell strain | 8 |
virus vaccine | 8 |
particularly high | 8 |
medical students | 8 |
renal disease | 8 |
testing positive | 8 |
min apgar | 8 |
response network | 8 |
possible cause | 8 |
infectious bronchitis | 8 |
negative controls | 8 |
important role | 8 |
level political | 8 |
neuraminidase inhibitor | 8 |
social determinants | 8 |
invasive mechanical | 8 |
study association | 8 |
authors declare | 8 |
framework convention | 8 |
medical staff | 8 |
infected people | 8 |
uenza viruses | 8 |
alcohol use | 8 |
underlying disease | 8 |
routine immunisation | 8 |
infected macaques | 8 |
receptor blockers | 8 |
lung cancer | 8 |
virus outbreak | 8 |
spectrum antiviral | 8 |
health policies | 8 |
uk government | 8 |
days later | 7 |
hispanic white | 7 |
sore throat | 7 |
political attention | 7 |
convulsive status | 7 |
diabetes mellitus | 7 |
economic impact | 7 |
health surveys | 7 |
ebola interim | 7 |
organising diffuse | 7 |
vaccine confidence | 7 |
increased dementia | 7 |
global economy | 7 |
median days | 7 |
social isolation | 7 |
racial minorities | 7 |
age groups | 7 |
mulbsta score | 7 |
patients received | 7 |
patient died | 7 |
analysis using | 7 |
anticancer treatment | 7 |
pneumonic sars | 7 |
neonatal deaths | 7 |
viral pneumonia | 7 |
good governance | 7 |
advanced dementia | 7 |
causal agent | 7 |
care will | 7 |
laboratory findings | 7 |
federal government | 7 |
will become | 7 |
decision instrument | 7 |
randomly selected | 7 |
existing health | 7 |
chest radiographic | 7 |
programme coverage | 7 |
cognitively normal | 7 |
vaccine allocation | 7 |
vascular disease | 7 |
causative agent | 7 |
emergency medicine | 7 |
respiratory samples | 7 |
community participation | 7 |
special administrative | 7 |
per week | 7 |
suffi cient | 7 |
clinical studies | 7 |
myeloid disorder | 7 |
us election | 7 |
chinese medical | 7 |
free world | 7 |
st century | 7 |
antihypertensive drugs | 7 |
control eff | 7 |
un security | 7 |
written informed | 7 |
offi cials | 7 |
control study | 7 |
basic reproduction | 7 |
mortality reductions | 7 |
coronary heart | 7 |
although many | 7 |
head injury | 7 |
less severe | 7 |
high prevalence | 7 |
antiviral therapy | 7 |
incubation periods | 7 |
high blood | 7 |
joint mission | 7 |
new virus | 7 |
yellow fever | 7 |
extras art | 7 |
newly discovered | 7 |
excessive alcohol | 7 |
infant mortality | 7 |
two decades | 7 |
none declared | 7 |
early warning | 7 |
per min | 7 |
embryonated chicken | 7 |
alkaline phosphatase | 7 |
ten countries | 7 |
rapid detection | 7 |
three times | 7 |
swab samples | 7 |
patient care | 7 |
nine livebirths | 7 |
protective immunity | 7 |
units per | 7 |
regional cooperation | 7 |
africa centres | 7 |
based isolation | 7 |
nasal swab | 7 |
based approach | 7 |
chemical irritants | 7 |
dementia might | 7 |
care professionals | 7 |
tumour necrosis | 7 |
will continue | 7 |
intrauterine vertical | 7 |
biopsy sample | 7 |
population ageing | 7 |
giant cells | 7 |
state council | 7 |
will also | 7 |
recombinant spike | 7 |
young people | 7 |
phase trials | 7 |
international cooperation | 7 |
clinical decision | 7 |
ncov outbreak | 7 |
minority ethnic | 7 |
human airway | 7 |
notifi cation | 7 |
expert panel | 7 |
neonatal throat | 7 |
risk reduction | 7 |
rapid response | 7 |
significantly different | 7 |
human development | 7 |
service delivery | 7 |
urgently needed | 7 |
wales hospital | 7 |
first patients | 7 |
cochrane review | 7 |
statistically significant | 7 |
defi nitions | 7 |
development bank | 7 |
two separate | 7 |
search terms | 7 |
infectious period | 7 |
sequence data | 7 |
three decades | 7 |
many people | 7 |
sufficient resources | 7 |
sectional study | 7 |
whitehall ii | 7 |
standard treatment | 7 |
clinical manifestations | 7 |
surveillance system | 7 |
gross national | 7 |
international public | 7 |
observational study | 7 |
southern china | 7 |
equitable access | 7 |
open lung | 7 |
disadvantaged populations | 7 |
tested negative | 7 |
interim assessment | 7 |
economic crisis | 7 |
primary cause | 7 |
eight controls | 7 |
intervention coverage | 7 |
limited number | 7 |
systolic blood | 7 |
detected viral | 7 |
genomic sequences | 7 |
transient myeloid | 7 |
skilled birth | 7 |
coronary artery | 7 |
emergency preparedness | 7 |
quality evidence | 7 |
secondary infections | 7 |
sleep disturbance | 7 |
viral antigen | 7 |
hubei province | 7 |
viral genome | 7 |
late life | 7 |
double labelling | 7 |
human macrophages | 7 |
disease prevention | 7 |
total number | 7 |
parainfluenza virus | 7 |
health issues | 7 |
oral poliovirus | 7 |
intellectual property | 7 |
gastrointestinal tract | 7 |
aff ect | 7 |
health regulation | 7 |
gastrointestinal symptoms | 7 |
zone iii | 7 |
general practitioners | 7 |
covid pandemic | 7 |
positive signals | 7 |
minority groups | 7 |
coeliac disease | 7 |
global alert | 7 |
assessment panel | 7 |
future outbreaks | 7 |
amoy gardens | 7 |
viral genomic | 7 |
gender inequality | 7 |
zone ii | 7 |
personal protection | 7 |
economic recession | 7 |
full autopsy | 7 |
task force | 7 |
child transmission | 7 |
necrosis factor | 7 |
mediterranean diet | 7 |
study population | 7 |
medical supplies | 7 |
wuhan university | 7 |
ethnic groups | 7 |
least two | 7 |
dangerous pathogens | 7 |
intestinal mucosa | 7 |
cancer centres | 7 |
pneumocyte hyperplasia | 7 |
longitudinal study | 7 |
com extras | 7 |
fi res | 7 |
international development | 7 |
early reporting | 7 |
eff ectively | 7 |
crisis response | 7 |
seed virus | 7 |
vaccine seed | 7 |
first reported | 7 |
received recent | 6 |
laboratory data | 6 |
gender norms | 6 |
intravenous remdesivir | 6 |
first weeks | 6 |
clinical benefit | 6 |
fed babies | 6 |
fatty liver | 6 |
relative risk | 6 |
sanitary conventions | 6 |
immune system | 6 |
critical care | 6 |
breaths per | 6 |
tissue damage | 6 |
data sharing | 6 |
single patient | 6 |
moderate ari | 6 |
vaccines based | 6 |
immunohistochemical staining | 6 |
medical sciences | 6 |
deaths per | 6 |
foreign medical | 6 |
common symptoms | 6 |
racial minority | 6 |
key epidemiological | 6 |
primary endpoint | 6 |
drug resistance | 6 |
one example | 6 |
better understand | 6 |
monitoring board | 6 |
insuffi cient | 6 |
actively infected | 6 |
oxygen support | 6 |
western pacifi | 6 |
statistical analysis | 6 |
reproductive health | 6 |
global covid | 6 |
early discharge | 6 |
breastmilk samples | 6 |
vaccine formulations | 6 |
sars viral | 6 |
exact test | 6 |
rmed cases | 6 |
several months | 6 |
public sector | 6 |
also found | 6 |
uenza preparedness | 6 |
febrile illness | 6 |
control programmes | 6 |
disease spread | 6 |
day mortality | 6 |
international monetary | 6 |
large number | 6 |
current outbreak | 6 |
outcome measures | 6 |
exponential trend | 6 |
monitoring project | 6 |
hearing impairment | 6 |
new drugs | 6 |
plasma levels | 6 |
otitis media | 6 |
alzheimer disease | 6 |
complement fixation | 6 |
old man | 6 |
younger children | 6 |
cytotoxic chemotherapy | 6 |
based cohort | 6 |
seropositive patients | 6 |
tract bleeding | 6 |
global strategy | 6 |
canine kidney | 6 |
private health | 6 |
study found | 6 |
initial phase | 6 |
randomised trials | 6 |
severe cases | 6 |
infl uence | 6 |
pressure control | 6 |
health agencies | 6 |
committee regarding | 6 |
drug users | 6 |
vaccine trials | 6 |
early transmission | 6 |
coronavirus associated | 6 |
whether sars | 6 |
reduced risk | 6 |
seasonal prophylaxis | 6 |
will allow | 6 |
rotavirus infection | 6 |
diagnosed cases | 6 |
cardiac arrest | 6 |
respiratory diseases | 6 |
development fi | 6 |
less education | 6 |
fi nding | 6 |
several countries | 6 |
virus isolated | 6 |
short term | 6 |
published online | 6 |
well established | 6 |
results show | 6 |
highly immunogenic | 6 |
high proportion | 6 |
amplifi cation | 6 |
increased concentrations | 6 |
hospital patients | 6 |
buffered saline | 6 |
virus receptors | 6 |
physical inactivity | 6 |
radiology suite | 6 |
hospital beds | 6 |
defi ne | 6 |
hiv treatment | 6 |
icu admission | 6 |
contact investigation | 6 |
intervention group | 6 |
pharmacological interventions | 6 |
care services | 6 |
hispanic black | 6 |
gross domestic | 6 |
reverse transcriptase | 6 |
disease burden | 6 |
one dose | 6 |
health spending | 6 |
reverse triage | 6 |
severe infections | 6 |
aortic aneurysm | 6 |
mg twice | 6 |
newborn infants | 6 |
care facility | 6 |
significant difference | 6 |
east asian | 6 |
brain tissue | 6 |
infection may | 6 |
died days | 6 |
chain reaction | 6 |
community mobilisation | 6 |
eye protection | 6 |
final responsibility | 6 |
virus rna | 6 |
phase trial | 6 |
extradition hearing | 6 |
international sanitary | 6 |
new evidence | 6 |
rhesus macaques | 6 |
aff ecting | 6 |
subgroup analyses | 6 |
hopkins university | 6 |
dementia living | 6 |
viral clearance | 6 |
infectious virus | 6 |
chest radiographs | 6 |
adult inpatients | 6 |
past two | 6 |
nan title | 6 |
hofbauer cells | 6 |
infant formula | 6 |
abdominal aortic | 6 |
antiviral drug | 6 |
first case | 6 |
monetary fund | 6 |
four months | 6 |
neurofilament light | 6 |
weak health | 6 |
suff ering | 6 |
electronic medical | 6 |
high viral | 6 |
unclear whether | 6 |
cognitive ability | 6 |
mortality ratio | 6 |
detect viral | 6 |
significant effect | 6 |
linked immunosorbent | 6 |
specifi cally | 6 |
rural areas | 6 |
transplacental transmission | 6 |
vero cell | 6 |
case management | 6 |
two open | 6 |
haemagglutinin gene | 6 |
chandipura viral | 6 |
ebola outbreaks | 6 |
dietary fibre | 6 |
health leaders | 6 |
darby canine | 6 |
serological evidence | 6 |
densely populated | 6 |
methylprednisolone mg | 6 |
mem i | 6 |
combination treatment | 6 |
electronic media | 6 |
confl ict | 6 |
chronic non | 6 |
rockefeller foundation | 6 |
reactive protein | 6 |
mainland china | 6 |
business coalition | 6 |
cell lymphomas | 6 |
vaccine production | 6 |
mass index | 6 |
study date | 6 |
important factor | 6 |
maternal antibody | 6 |
three countries | 6 |
acute kidney | 6 |
next day | 6 |
years previously | 6 |
pcr testing | 6 |
severe complications | 6 |
seafood market | 6 |
fault lines | 6 |
un agencies | 6 |
stage renal | 6 |
radiographic changes | 6 |
liver disease | 6 |
type i | 6 |
medical services | 6 |
patients aged | 6 |
polymerase chain | 6 |
urban areas | 6 |
patent herbal | 6 |
cruise ship | 6 |
trade restrictions | 6 |
recent years | 6 |
care staff | 6 |
protective effect | 6 |
pathogenic avian | 6 |
global governance | 6 |
quantitative rt | 6 |
risk communication | 6 |
medullary thyroid | 6 |
patients presented | 6 |
health crisis | 6 |
health protection | 6 |
course model | 6 |
might occur | 6 |
per livebirths | 6 |
medical education | 6 |
security agenda | 6 |
institutional review | 6 |
advisory group | 6 |
cytopathic effect | 6 |
days iqr | 6 |
public hospitals | 6 |
kidney injury | 6 |
endemic regions | 6 |
clinical diagnosis | 6 |
small bowel | 6 |
eligible patients | 6 |
rapid spread | 6 |
variant sequences | 6 |
within countries | 6 |
human population | 6 |
age group | 6 |
hyaline membranes | 6 |
fatal outcome | 6 |
healthy volunteers | 6 |
acute upper | 6 |
health strategy | 6 |
free health | 6 |
negative results | 6 |
global engagement | 6 |
positive samples | 6 |
russian federation | 6 |
nasopharyngeal aspirates | 6 |
pregnant woman | 6 |
infection might | 6 |
viral antigens | 6 |
may lead | 6 |
international response | 6 |
structural competency | 6 |
bacterial infections | 6 |
endemic areas | 6 |
squamous metaplasia | 6 |
world economic | 6 |
healthy people | 6 |
many patients | 6 |
thyroid carcinoma | 6 |
family carers | 6 |
spike glycoprotein | 6 |
people without | 6 |
pandemic alert | 6 |
travel restrictions | 6 |
international labour | 6 |
virus stock | 6 |
disease associated | 6 |
vaccine administered | 6 |
longitudinal cohort | 6 |
participant data | 6 |
international law | 6 |
prospective studies | 6 |
ii cohort | 6 |
review board | 6 |
dementia care | 6 |
us government | 6 |
active cancer | 6 |
disease course | 6 |
domestic product | 6 |
like immunoreactivity | 5 |
rapid economic | 5 |
possible role | 5 |
cancer monitoring | 5 |
whole genome | 5 |
lessons learnt | 5 |
ageing population | 5 |
neighbouring countries | 5 |
vol september | 5 |
wearing masks | 5 |
tubular epithelial | 5 |
pathological findings | 5 |
one health | 5 |
china national | 5 |
airborne transmission | 5 |
acquired pneumonia | 5 |
prevention programmes | 5 |
opportunistic infections | 5 |
normal cognition | 5 |
vaccine candidate | 5 |
histological changes | 5 |
four teenagers | 5 |
seroprevalence estimates | 5 |
might make | 5 |
human resource | 5 |
heart failure | 5 |
chorionic villi | 5 |
viral respiratory | 5 |
coronavirus cancer | 5 |
extracorporeal membrane | 5 |
people older | 5 |
developed respiratory | 5 |
boost vaccination | 5 |
airway epithelial | 5 |
dose regimens | 5 |
un secretary | 5 |
positive rt | 5 |
articles published | 5 |
histological examination | 5 |
methylprednisolone dose | 5 |
additional incident | 5 |
hiv programmes | 5 |
laboratory tests | 5 |
next years | 5 |
might explain | 5 |
core capacity | 5 |
calcitonin gene | 5 |
technical guidance | 5 |
poverty level | 5 |
analysis laboratory | 5 |
alveolar walls | 5 |
sample processing | 5 |
fi gures | 5 |
respiratory rate | 5 |
working party | 5 |
exercise training | 5 |
aids patients | 5 |
rapid global | 5 |
infected infants | 5 |
ill health | 5 |
colleagues report | 5 |
lombardy region | 5 |
contingency management | 5 |
membrane oxygenation | 5 |
list analysis | 5 |
aminoacid residues | 5 |
infection caused | 5 |
postexposure treatment | 5 |
enteric coronaviruses | 5 |
creatine kinase | 5 |
three studies | 5 |
also collected | 5 |
analysis association | 5 |
moderate dementia | 5 |
basic science | 5 |
measles virus | 5 |
ethnic disparities | 5 |
labour force | 5 |
deaths averted | 5 |
viral vectors | 5 |
county medical | 5 |
blood sample | 5 |
abdominal pain | 5 |
international institutions | 5 |
comprehensive response | 5 |
general anaesthesia | 5 |
fatal respiratory | 5 |
since feb | 5 |
foreign students | 5 |
first step | 5 |
different groups | 5 |
patients might | 5 |
political will | 5 |
gilead sciences | 5 |
two doses | 5 |
south asian | 5 |
lean body | 5 |
pandemic preparedness | 5 |
nervous system | 5 |
hospitalized patients | 5 |
new approaches | 5 |
health ministry | 5 |
see also | 5 |
sleep duration | 5 |
york city | 5 |
type ii | 5 |
assisted ventilation | 5 |
health organisation | 5 |
health risk | 5 |
emergency management | 5 |
relatively small | 5 |
inactivated poliovirus | 5 |
ected countries | 5 |
samples taken | 5 |
level meeting | 5 |
developed fever | 5 |
ciliated cells | 5 |
bat origin | 5 |
test results | 5 |
two months | 5 |
estimated case | 5 |
saved tool | 5 |
electron microscope | 5 |
syndrome virus | 5 |
research funders | 5 |
uk national | 5 |
clinical onset | 5 |
regional health | 5 |
offi ces | 5 |
clinical evidence | 5 |
showed positive | 5 |
administered intramuscularly | 5 |
fourteen rabbits | 5 |
less common | 5 |
cardiac injury | 5 |
might help | 5 |
cases reported | 5 |
clinical analysis | 5 |
required oxygen | 5 |
future generations | 5 |
serum albumin | 5 |
made substantial | 5 |
health implications | 5 |
ct scans | 5 |
patient exposure | 5 |
whether covid | 5 |
community survey | 5 |
studies suggest | 5 |
fi nanced | 5 |
took place | 5 |
international trade | 5 |
severe tbi | 5 |
economic consequences | 5 |
disease prevalence | 5 |
ebola emergency | 5 |
immunosorbent assay | 5 |
diagnostic value | 5 |
significant differences | 5 |
substantial intellectual | 5 |
adverse outcomes | 5 |
target antigen | 5 |
years follow | 5 |
transmissible gastroenteritis | 5 |
year period | 5 |
reverse causation | 5 |
ensure access | 5 |
room temperature | 5 |
substantial titres | 5 |
care fi | 5 |
humoral immune | 5 |
monkey kidney | 5 |
parental leave | 5 |
mortality associated | 5 |
health disparities | 5 |
adaptive immune | 5 |
live attenuated | 5 |
older age | 5 |
testing capacity | 5 |
labour organization | 5 |
reduced dementia | 5 |
type myocardial | 5 |
team members | 5 |
polymerase gene | 5 |
mild acute | 5 |
international collaboration | 5 |
plus supportive | 5 |
pcr assay | 5 |
develop covid | 5 |
african americans | 5 |
identifi cation | 5 |
eight patients | 5 |
public services | 5 |
eradicate poliomyelitis | 5 |
fi rms | 5 |
described previously | 5 |
dendritic cells | 5 |
may cause | 5 |
binding domain | 5 |
health consequences | 5 |
patients requiring | 5 |
megakaryoblastic leukaemia | 5 |
administrative region | 5 |
medical team | 5 |
pcr products | 5 |
health threat | 5 |
public good | 5 |
global fi | 5 |
even greater | 5 |
general assembly | 5 |
made available | 5 |
acute encephalitis | 5 |
cancer treatments | 5 |
targeted therapy | 5 |
specific health | 5 |
inclusion criteria | 5 |
light microscopy | 5 |
please refer | 5 |
negative control | 5 |
physical health | 5 |
short time | 5 |
infection occurred | 5 |
vectored covid | 5 |
life dementia | 5 |
nancial crisis | 5 |
heterologous prime | 5 |
radiological characteristics | 5 |
antiretroviral drugs | 5 |
laboratory network | 5 |
save lives | 5 |
uk coronavirus | 5 |
care alone | 5 |
children aged | 5 |
nongovernmental organisations | 5 |
secretary general | 5 |
preparedness framework | 5 |
well known | 5 |
multivariate analysis | 5 |
early life | 5 |
nile virus | 5 |
like symptoms | 5 |
analysis plan | 5 |
available data | 5 |
care planning | 5 |
people might | 5 |
pneumonic paediatric | 5 |
reducing maternal | 5 |
ulcerative jejunitis | 5 |
widely used | 5 |
corresponding authors | 5 |
two new | 5 |
epidemic curve | 5 |
serum calcitonin | 5 |
high titres | 5 |
donated blood | 5 |
chinese academy | 5 |
sample collection | 5 |
evidence supports | 5 |
human populations | 5 |
incident management | 5 |
gene therapy | 5 |
candidate covid | 5 |
acute megakaryoblastic | 5 |
clinical efficacy | 5 |
among others | 5 |
respiratory system | 5 |
law enforcement | 5 |
health initiative | 5 |
health ministers | 5 |
hospital authority | 5 |
poorer countries | 5 |
also need | 5 |
crucial importance | 5 |
cells per | 5 |
generating procedures | 5 |
antirabies igg | 5 |
care work | 5 |
combination group | 5 |
collective action | 5 |
might cause | 5 |
participants aged | 5 |
representative sample | 5 |
aerobic exercise | 5 |
young adults | 5 |
phase clinical | 5 |
endemic countries | 5 |
remdesivir recipients | 5 |
global trade | 5 |
mg every | 5 |
global research | 5 |
effective way | 5 |
literature search | 5 |
prevent cognitive | 5 |
healthcare settings | 5 |
infected adults | 5 |
present study | 5 |
governments must | 5 |
workplace visits | 5 |
blood cells | 5 |
care coverage | 5 |
outbreak control | 5 |
circulating mononuclear | 5 |
national level | 5 |
economic diff | 5 |
secondary bacterial | 5 |
service providers | 5 |
additional cases | 5 |
intellectual input | 5 |
inflammatory response | 5 |
sexual transmission | 5 |
table shows | 5 |
placebo recipients | 5 |
rapid diagnostic | 5 |
birth attendance | 5 |
org en | 5 |
king county | 5 |
infectious dose | 5 |
health efforts | 5 |
trial efficacy | 5 |
clinical care | 5 |
confirmed sars | 5 |
effi cient | 5 |
roche diagnostics | 5 |
unknown cause | 5 |
fatal severe | 5 |
will provide | 5 |
coronavirus study | 5 |
alveolar epithelial | 5 |
ace receptor | 5 |
computerised cognitive | 5 |
viral isolates | 5 |
cell response | 5 |
sex work | 5 |
poor health | 5 |
environmental policies | 5 |
elderly patients | 5 |
dementia compared | 5 |
airborne precautions | 5 |
excess mortality | 5 |
lymphocyte transformation | 5 |
influenza infection | 5 |
available evidence | 5 |
health expenditures | 5 |
red blood | 5 |
health preparedness | 5 |
general hospital | 5 |
among hiv | 5 |
routine pathology | 5 |
tissue tropism | 5 |
warfare analysis | 5 |
lung disease | 5 |
artery disease | 5 |
cell responses | 5 |
similar trend | 5 |
major health | 5 |
renal function | 5 |
work together | 5 |
take place | 5 |
mature calcitonin | 5 |
broader health | 5 |
old male | 5 |
beneficial effect | 5 |
stem cells | 5 |
day history | 5 |
increased transmission | 5 |
mortality among | 5 |
factors might | 5 |
active viral | 5 |
global outbreak | 5 |
health departments | 5 |
last year | 5 |
clinical research | 5 |
us food | 5 |
elisa based | 5 |
outcome measure | 5 |
health benefits | 5 |
might reduce | 5 |
cynomolgus macaques | 5 |
health infrastructure | 5 |
results showed | 5 |
hospital surge | 5 |
mild symptoms | 5 |
positive result | 5 |
hospital capacity | 5 |
patient showed | 5 |
glass enclosure | 5 |
population groups | 5 |
experimentally infected | 5 |
chinese people | 5 |
effective treatment | 5 |
lateral ventricles | 5 |
recombinant viral | 5 |
deaths worldwide | 5 |
received rad | 5 |
might include | 5 |
antiretroviral treatment | 5 |
short period | 5 |
global burden | 5 |
among infants | 5 |
significant risk | 5 |
controlling covid | 5 |
asian countries | 5 |
per patient | 5 |
chinese traditional | 5 |
case scenario | 5 |
preventing dementia | 5 |
major antigenic | 5 |
infected individuals | 5 |
us health | 5 |
peer review | 5 |
psychological torture | 5 |
accession number | 5 |
rna polymerase | 5 |
government agencies | 5 |
disposition classification | 5 |
probable person | 5 |
ill covid | 4 |
many different | 4 |
socioeconomic status | 4 |
otherwise healthy | 4 |
hmp belmarsh | 4 |
basic health | 4 |
ovarian cancer | 4 |
maximum number | 4 |
black lives | 4 |
porcine reproductive | 4 |
essential services | 4 |
nosocomial infections | 4 |
health situation | 4 |
well documented | 4 |
negative diarrhoea | 4 |
social factors | 4 |
acute porphyria | 4 |
two hospitals | 4 |
cholinesterase inhibitors | 4 |
several reasons | 4 |
cumulative cases | 4 |
functional decline | 4 |
respond rapidly | 4 |
unpublished data | 4 |
staphylococcus aureus | 4 |
predictive value | 4 |
endemic area | 4 |
scientific evidence | 4 |
clinical laboratories | 4 |
bronchoalveolar lavage | 4 |
external assessment | 4 |
patient cohort | 4 |
seven patients | 4 |
logistic regression | 4 |
china clinical | 4 |
expert group | 4 |
health event | 4 |
poor countries | 4 |
six countries | 4 |
african american | 4 |
ethical schools | 4 |
nasopharyngeal aspirate | 4 |
gathering events | 4 |
significant benefits | 4 |
research institute | 4 |
advance care | 4 |
secondary cases | 4 |
basic research | 4 |
international regulations | 4 |
berna biotech | 4 |
extradition proceedings | 4 |
tumour cells | 4 |
reverse transcription | 4 |
sialic acids | 4 |
take responsibility | 4 |
african governments | 4 |
igg detection | 4 |
tuberculosis cases | 4 |
care home | 4 |
disease trends | 4 |
executive director | 4 |
immune complexes | 4 |
unintended consequences | 4 |
international severe | 4 |
virus excretion | 4 |
adverse event | 4 |
chest radiography | 4 |
move towards | 4 |
many health | 4 |
justifi cation | 4 |
chronic disease | 4 |
asian descent | 4 |
guangdong province | 4 |
common sequence | 4 |
african ebola | 4 |
care national | 4 |
hepatitis virus | 4 |
system disease | 4 |
olfactory epithelium | 4 |
like disease | 4 |
central nervous | 4 |
tract specimens | 4 |
retrospective review | 4 |
parainfluenza viruses | 4 |
many governments | 4 |
health impacts | 4 |
patient management | 4 |
evidence suggesting | 4 |
predicting mortality | 4 |
fetal distress | 4 |
directigen flu | 4 |
nested rt | 4 |
pneumonia outbreak | 4 |
lymphoid tissue | 4 |
species barrier | 4 |
art web | 4 |
received chemotherapy | 4 |
showed bilateral | 4 |
median incubation | 4 |
major source | 4 |
fi brosis | 4 |
also important | 4 |
family carer | 4 |
public trust | 4 |
aids epidemic | 4 |
major public | 4 |
tuberculosis control | 4 |
outcomes among | 4 |
expanded programme | 4 |
large outbreak | 4 |
six months | 4 |
hospitals across | 4 |
ordinal scale | 4 |
community members | 4 |
also provide | 4 |
next months | 4 |
medical schools | 4 |
ten times | 4 |
discovered coronavirus | 4 |
orf ab | 4 |
protective factors | 4 |
epidemic threat | 4 |
existing immunity | 4 |
postmortem lung | 4 |
treatment outcomes | 4 |
virus type | 4 |
public goods | 4 |
mab hml | 4 |
cell proliferation | 4 |
mutation rate | 4 |
might result | 4 |
major cause | 4 |
one brain | 4 |
staff working | 4 |
ethics committee | 4 |
laboratory results | 4 |
pandemic date | 4 |
vaccine efficacy | 4 |
cystic fibrosis | 4 |
rapid information | 4 |
higher rates | 4 |
data capture | 4 |
family contacts | 4 |
younger age | 4 |
services provided | 4 |
among countries | 4 |
randomized trial | 4 |
spread disease | 4 |
natural resources | 4 |
category patients | 4 |
mouse hepatitis | 4 |
information systems | 4 |
protection study | 4 |
response plan | 4 |
interpandemic influenza | 4 |
amyloid pet | 4 |
air changes | 4 |
oropharyngeal swabs | 4 |
based health | 4 |
effect size | 4 |
media attention | 4 |
cell suspension | 4 |
subgroup analysis | 4 |
vital registration | 4 |
high number | 4 |
three days | 4 |
severe bacterial | 4 |
classification system | 4 |
advanced hiv | 4 |
lower risk | 4 |
oedema fluid | 4 |
donated facilities | 4 |
study findings | 4 |
gender systems | 4 |
epidemiological transitions | 4 |
laboratory accident | 4 |
national surveillance | 4 |
major concern | 4 |
outbreaks strike | 4 |
aggregate utility | 4 |
rad vector | 4 |
bronchial epithelial | 4 |
one visitor | 4 |
viral genomes | 4 |
gestational weeks | 4 |
ventilatory support | 4 |
key laboratory | 4 |
top priority | 4 |
haemagglutinin cleavage | 4 |
pandemic emergency | 4 |
first trimester | 4 |
hormonal therapy | 4 |
cm water | 4 |
bacterial cultures | 4 |
also reported | 4 |
calcitonin precursors | 4 |
virus antigen | 4 |
new infections | 4 |
obtained data | 4 |
rst case | 4 |
cluster surveys | 4 |
bacterial pneumonia | 4 |
infectious materials | 4 |
two western | 4 |
international partners | 4 |
nucleotide sequence | 4 |
respiratory protection | 4 |
pcr test | 4 |
infective dose | 4 |
must consider | 4 |
closely linked | 4 |
strongly associated | 4 |
requiring admission | 4 |
verifi cation | 4 |
also detected | 4 |
estimates suggest | 4 |
control practices | 4 |
including people | 4 |
retinal blood | 4 |
chinese health | 4 |
healthy children | 4 |
within years | 4 |
acute pancreatitis | 4 |
potential effect | 4 |
data will | 4 |
eastern mediterranean | 4 |
health delivery | 4 |
operational feasibility | 4 |
daily orally | 4 |
malignant histiocytosis | 4 |
national key | 4 |
zip code | 4 |
mild tbi | 4 |
body weight | 4 |
secondary contact | 4 |
open reading | 4 |
household contacts | 4 |
international financial | 4 |
patient contacts | 4 |
death toll | 4 |
dromedary camels | 4 |
us national | 4 |
refugee centres | 4 |
still needs | 4 |
disaster management | 4 |
must now | 4 |
patients required | 4 |
health importance | 4 |
linked sialic | 4 |
colonial administrators | 4 |
brain aspirate | 4 |
maternal death | 4 |
standardised data | 4 |
two trials | 4 |
seriously ill | 4 |
china will | 4 |
aid use | 4 |
health diplomacy | 4 |
electronic data | 4 |
first report | 4 |
central india | 4 |
recent infection | 4 |
provide clinical | 4 |
six cases | 4 |
among adults | 4 |
resource requirements | 4 |
south asians | 4 |
staffi ng | 4 |
dementia within | 4 |
primary antibody | 4 |
international effort | 4 |
transmission will | 4 |
advisory committee | 4 |
educational attainment | 4 |
related coronavirus | 4 |
best practices | 4 |
lactate dehydrogenase | 4 |
statistical significance | 4 |
resource allocation | 4 |
particular risk | 4 |
private fi | 4 |
virus origins | 4 |
nasal swabs | 4 |
xenophobic responses | 4 |
tract illness | 4 |
applied biosystems | 4 |
cancer screening | 4 |
lyophilised formulation | 4 |
sequence variations | 4 |
global vaccine | 4 |
consensus defi | 4 |
medical board | 4 |
live influenza | 4 |
host immune | 4 |
conventional inactivated | 4 |
syndrome isolation | 4 |
mortem examination | 4 |
pivotal role | 4 |
face masks | 4 |
early march | 4 |
protection afforded | 4 |
strain differences | 4 |
base substitutions | 4 |
also needs | 4 |
assessment tool | 4 |
towards greater | 4 |
black death | 4 |
four times | 4 |
aspartate aminotransferase | 4 |
health achievement | 4 |
hearing aid | 4 |
current us | 4 |
antiviral activity | 4 |
community mobility | 4 |
current covid | 4 |
international classification | 4 |
outbreak prevention | 4 |
virus replication | 4 |
aggressive clinical | 4 |
ciliated epithelial | 4 |
acute coronary | 4 |
haem biosynthesis | 4 |
university hospital | 4 |
confidence intervals | 4 |
different types | 4 |
depressive symptoms | 4 |
antenatal care | 4 |
golgi apparatus | 4 |
developed symptoms | 4 |
strain rabies | 4 |
sputum samples | 4 |
vaccine manufacturers | 4 |
risk management | 4 |
will reduce | 4 |
foster city | 4 |
avium intracellulare | 4 |
diagnostic testing | 4 |
postmortem samples | 4 |
early phase | 4 |
total rna | 4 |
outbreak alert | 4 |
funding source | 4 |
developed sars | 4 |
fight aids | 4 |
two countries | 4 |
much greater | 4 |
newborn nurseries | 4 |
dementia prevalence | 4 |
case definitions | 4 |
small studies | 4 |
kg body | 4 |
specific incidence | 4 |
fi fth | 4 |
amyloid negative | 4 |
property rights | 4 |
caring responsibilities | 4 |
cacy studies | 4 |
dry cough | 4 |
economic agenda | 4 |
mortem lung | 4 |
covid epidemic | 4 |
appropriate biosafety | 4 |
medical tourism | 4 |
independent experts | 4 |
whereas others | 4 |
community groups | 4 |
appendix key | 4 |
many new | 4 |
revised ihr | 4 |
health will | 4 |
best chance | 4 |
contact history | 4 |
middleincome countries | 4 |
virus may | 4 |
categorical variables | 4 |
royal college | 4 |
require intensive | 4 |
injection site | 4 |
emergency medical | 4 |
confirmed chandipura | 4 |
room air | 4 |
serum fdp | 4 |
sialic acid | 4 |
heart protection | 4 |
peaceful protesters | 4 |
treated within | 4 |
prevent infection | 4 |
annual report | 4 |
frozen vaccine | 4 |
adequately tolerated | 4 |
important lessons | 4 |
four decades | 4 |
several years | 4 |
current administration | 4 |
developed mers | 4 |
health technology | 4 |
research funding | 4 |
least days | 4 |
hypertensive patients | 4 |
arab countries | 4 |
intravascular coagulation | 4 |
discharged early | 4 |
transcriptase pcr | 4 |
new influenza | 4 |
clinically significant | 4 |
economic downturn | 4 |
trans mission | 4 |
clinical findings | 4 |
nitric oxide | 4 |
infectious outbreaks | 4 |
views expressed | 4 |
community must | 4 |
capillary leak | 4 |
significant correlation | 4 |
lymphocyte population | 4 |
three major | 4 |
quarantine measures | 4 |
month recovery | 4 |
substantial reductions | 4 |
support national | 4 |
rabies antibody | 4 |
pork meat | 4 |
receiving treatment | 4 |
less effective | 4 |
thrice daily | 4 |
congenital heart | 4 |
directed towards | 4 |
intrauterine infection | 4 |
small numbers | 4 |
previous experiences | 4 |
tissue sections | 4 |
commercial determinants | 4 |
national incident | 4 |
pacific region | 4 |
first patient | 4 |
like many | 4 |
csf samples | 4 |
three months | 4 |
also show | 4 |
commonest cause | 4 |
biosafety level | 4 |
pharmaceutical companies | 4 |
seroprevalence data | 4 |
potential public | 4 |
confirmed influenza | 4 |
sars infection | 4 |
additional resources | 4 |
least one | 4 |
normal population | 4 |
actual mortality | 4 |
oral neuraminidase | 4 |
estimated million | 4 |
full range | 4 |
milk products | 4 |
broad range | 4 |
acute hospital | 4 |
clinical picture | 4 |
illness onset | 4 |
pneumonic infections | 4 |
runny nose | 4 |
levetiracetam versus | 4 |
physical examination | 4 |
emergency plan | 4 |
nonalcoholic steatohepatitis | 4 |
syndrome epidemic | 4 |
collection forms | 4 |
effective vaccines | 4 |
month lockdown | 4 |
tuberculosis services | 4 |
five target | 4 |
relatively high | 4 |
un mission | 4 |
asked questions | 4 |
risk perception | 4 |
associated nephritis | 4 |
testing strategies | 4 |
direct contact | 4 |
recent report | 4 |
samples tested | 4 |
week follow | 4 |
statistical analyses | 4 |
daily cases | 4 |
health approach | 4 |
job losses | 4 |
africa needs | 4 |
another study | 4 |
will affect | 4 |
ideal cardiovascular | 4 |
recombinant viruses | 4 |
china cdc | 4 |
forest fi | 4 |
extrathyroid diseases | 4 |
term follow | 4 |
experimental infection | 4 |
new cases | 4 |
previously healthy | 4 |
bilateral pneumonia | 4 |
far less | 4 |
cd staining | 4 |
sleep disturbances | 4 |
market forces | 4 |
resistant tuberculosis | 4 |
ct images | 4 |
bilateral ground | 4 |
old age | 4 |
fl ows | 4 |
greater risk | 4 |
first cases | 4 |
common variant | 4 |
using ct | 4 |
geometric mean | 4 |
technical support | 4 |
deaths due | 4 |
leak syndrome | 4 |
teaching hospital | 4 |
aids relief | 4 |
among contacts | 4 |
surveillance systems | 4 |
research council | 4 |
previously reported | 4 |
structural protein | 4 |
frequently asked | 4 |
global action | 4 |
sex selection | 4 |
management system | 4 |
newly emerged | 4 |
might increase | 4 |
vaccine strain | 4 |
disease caused | 4 |
based vaccine | 4 |
international consensus | 4 |
also likely | 4 |
also seen | 4 |
maternal health | 4 |
urgent need | 4 |
priority setting | 4 |
specific mortality | 4 |
limited access | 4 |
much lower | 4 |
cause serious | 4 |
without borders | 4 |
organ transplantation | 4 |
economic forum | 4 |
clinical outcome | 4 |
economic loss | 4 |
using hearing | 4 |
antibiotics used | 4 |
unusual severity | 4 |
work closely | 4 |
data available | 4 |
urinary fibrin | 4 |
arterial oxygen | 4 |
health health | 4 |
line health | 4 |
income per | 4 |
continuous variables | 4 |
study drug | 4 |
vascular risk | 4 |
health goal | 4 |
viral transmission | 4 |
information system | 4 |
humanitarian aff | 4 |
volume loss | 4 |
elderly persons | 4 |
national audit | 4 |
safety concerns | 4 |
international agencies | 4 |
low risk | 4 |
changes per | 4 |
large intestine | 4 |
transport medium | 4 |
fatality ratio | 4 |
new international | 4 |
adenoviral vectors | 4 |
medical professionals | 4 |
specific rt | 4 |
clinical laboratory | 4 |
rotary international | 4 |
medical attention | 4 |
humanitarian crisis | 4 |
neutralisation tests | 4 |
much needed | 4 |
population study | 4 |
blood mononuclear | 4 |
vaccine effectiveness | 4 |
future research | 4 |
medical male | 4 |
global economic | 4 |
study reported | 4 |
real time | 4 |
clinical presentation | 4 |
nasopharyngeal swab | 4 |
sars patient | 4 |
months later | 4 |
also showed | 4 |
household transmission | 4 |
aid recipient | 4 |
population health | 4 |
small proportion | 4 |
natural infection | 4 |
confounding factors | 4 |
high serum | 4 |
across countries | 4 |
results suggest | 4 |
residual confounding | 4 |
home residents | 4 |
laboratory investigations | 4 |
group activities | 4 |
index patient | 4 |
growth hormone | 4 |
current evidence | 4 |
washington state | 4 |
us administration | 4 |
ii receptor | 4 |
prevent future | 4 |
emergent pathogens | 4 |
prominent nucleoli | 4 |
various organs | 4 |
political declaration | 4 |
consecutive sections | 4 |
unpaid labour | 4 |
medical neglect | 4 |
anhui province | 4 |
health clinics | 4 |
diamond princess | 4 |
health fi | 4 |
sequence variants | 4 |
one year | 4 |
central africa | 4 |
expert panellists | 4 |
male sex | 4 |
ten children | 4 |
public policies | 4 |
genomic characterisation | 4 |
air quality | 4 |
aid donor | 4 |
moral schools | 4 |
corticosteroid treatment | 4 |
potential impact | 4 |
medical personnel | 4 |
dengue fever | 4 |
world trade | 4 |
indicator cluster | 4 |
health concern | 4 |
china medical | 4 |
multiple indicator | 4 |
mosquito bites | 4 |
cell line | 4 |
hiv transmission | 4 |
four major | 4 |
personal fees | 4 |
clinically relevant | 4 |
many clinical | 4 |
individual participant | 4 |
carbon monoxide | 4 |
study showed | 4 |
included participants | 4 |
dementia outcomes | 4 |
per dose | 4 |
taken together | 4 |
refl ects | 4 |
tuberculosis programmes | 4 |
universal face | 4 |
cardio vascular | 4 |
severely affected | 4 |
potential eff | 4 |
data safety | 4 |
nasal cannula | 4 |
care coalitions | 4 |
zhongnan hospital | 4 |
chest signs | 4 |
development indicators | 4 |
sectional survey | 4 |
population attributable | 4 |
probable cases | 4 |
higher proportion | 4 |
lockdown measures | 4 |
measles immunisation | 4 |
postexposure prophylaxis | 4 |
enough resources | 4 |
type pneumocyte | 4 |
including influenza | 4 |
weighted paf | 4 |
psychological symptoms | 4 |
china joint | 4 |
mass drug | 4 |
reassortant virus | 4 |
time period | 4 |
tissue collection | 4 |
hdcs rabies | 4 |
one secondary | 4 |
international assistance | 4 |
intravenous prednisolone | 4 |
symptoms included | 4 |
us population | 4 |
using data | 4 |
cns involvement | 4 |
economic disruption | 4 |
low levels | 4 |
environmental health | 4 |
united kingdom | 4 |
indonesian children | 4 |
blood vessels | 4 |
ezv outbreak | 4 |
american health | 4 |
ective interventions | 4 |
epidemiological determinants | 4 |
tear gas | 4 |